Brokerages expect AxoGen, Inc (NASDAQ:AXGN) to announce earnings per share (EPS) of ($0.06) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for AxoGen’s earnings. AxoGen also reported earnings per share of ($0.06) in the same quarter last year. The business is expected to announce its next earnings report on Wednesday, August 1st.
On average, analysts expect that AxoGen will report full-year earnings of ($0.18) per share for the current fiscal year. For the next fiscal year, analysts expect that the firm will post earnings of $0.00 per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover AxoGen.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Monday, April 30th. The medical equipment provider reported ($0.11) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.11). The firm had revenue of $17.30 million for the quarter, compared to the consensus estimate of $17.16 million. AxoGen had a negative return on equity of 61.66% and a negative net margin of 18.83%. The firm’s revenue for the quarter was up 41.8% on a year-over-year basis.
AxoGen traded up $0.65, hitting $48.40, during trading hours on Thursday, Marketbeat.com reports. 308,615 shares of the stock traded hands, compared to its average volume of 347,830. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.81 and a current ratio of 3.32. The company has a market cap of $1.67 billion, a PE ratio of -156.13 and a beta of 0.05. AxoGen has a 1 year low of $14.25 and a 1 year high of $51.70.
In other news, SVP Shawn F. Mccarrey sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $43.47, for a total value of $434,700.00. Following the sale, the senior vice president now owns 33,057 shares in the company, valued at $1,436,987.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.86% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of AXGN. Schwab Charles Investment Management Inc. boosted its stake in shares of AxoGen by 33.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 142,239 shares of the medical equipment provider’s stock worth $4,026,000 after buying an additional 35,550 shares during the last quarter. Aperio Group LLC acquired a new position in AxoGen in the 4th quarter worth about $412,000. Teacher Retirement System of Texas acquired a new position in AxoGen in the 4th quarter worth about $271,000. Swiss National Bank acquired a new position in AxoGen in the 4th quarter worth about $1,367,000. Finally, Catalyst Capital Advisors LLC raised its holdings in AxoGen by 15.7% in the 4th quarter. Catalyst Capital Advisors LLC now owns 35,300 shares of the medical equipment provider’s stock worth $999,000 after purchasing an additional 4,800 shares during the period. Hedge funds and other institutional investors own 75.51% of the company’s stock.
AxoGen Company Profile
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.